Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma
暂无分享,去创建一个
D. Brander | T. Shea | C. Decastro | D. Rizzieri | Joseph O. Moore | J. Gockerman | A. Beaven | L. Diehl | J. Moore